



ASX Company Announcement

Sun Biomedical Completes First Phase of Oraline® Testing

27 June 2014

Australian biotechnology and medical device company Sun Biomedical Limited (ASX: SBN) is pleased to announce that it has completed the first phase of testing of the new Oraline® device by an independent industry accredited laboratory.

The devices tested spiked samples at $\pm 50\%$ of the cut-off level for all drugs. Tests demonstrated significant improvement in saliva flow as a result of housing modifications comparing to the previous Oraline® device. However, the results also revealed an existing problem with the current immuno strip, as there was a significant number of false negative signals.

The Company recognises the specificity issue of the strip and is currently in discussions with its manufacturing partners in order to find the best solution.

“We are aware of the issue with the specificity of our strips and will endeavour thorough investigations with our existing partners and explore new options in order to achieve the best working solution for our new Oraline® product. Specificity problems are not uncommon for the drug testing industry and refinement represents a normal component of the product development cycle” said Howard Digby, Executive Chairman of Sun Biomedical.

The Company also remains on track with the development of a new dual strip version of Oraline® and will be updating the market as we progress. The release of this and upcoming versions of Oraline® are well timed to capitalise on a worldwide trend towards convenient saliva based occupational drug testing.

The Board will also continue to explore licensing and acquisition opportunities with the view of expanding the Company’s pipeline of medical device products.

About Sun Biomedical:

Sun Biomedical Limited is an international biotechnology company with assets in the area of occupational drug testing. The Company is commercialising new improved versions of its “Oraline®” hand held multi drug test device while also looking to increase its biotechnology investments.

For more information about Sun Biomedical visit its corporate website at www.sunbiomed.com.au

Howard Digby
Executive Chairman
+61 434 987 750